Sonoma Pharmaceuticals (SNOA) EBIT Margin (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly EBIT Margin of 15.59% in Q4 2025, down 159.24% quarter-over-quarter from 6.01% in Q3 2025, and up 1334.0% on a YoY basis from 1.09% in Q4 2024.
Sonoma Pharmaceuticals (SNOA) EBIT Margin (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' EBIT Margin history runs 16 years deep, the most recent figure standing at 15.59% for Q4 2025.
- In Q4 2025, EBIT Margin rose 1334.0% year-over-year to 15.59%; the TTM figure through Dec 2025 stood at 15.61% (up 1633.0% YoY), while the FY2025 annual figure was 25.97%, up 1095.0% from the prior year.
- EBIT Margin was 15.59% for Q4 2025 at Sonoma Pharmaceuticals, down from 6.01% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 6.01% in Q3 2025 to a low of 133.16% in Q1 2022.
- Historically, EBIT Margin has averaged 39.63% across 5 years, with a median of 28.1% in 2024.
- The sharpest annual moves came in 2021 and 2023: EBIT Margin slumped 5569 bps in 2021, then jumped 9510 bps in 2023.
- A 5-year view of EBIT Margin shows it stood at 33.01% in 2021, then plunged by 89 bps to 62.3% in 2022, then jumped by 57 bps to 26.9% in 2023, then fell by 8 bps to 28.93% in 2024, then jumped by 46 bps to 15.59% in 2025.
- The last three EBIT Margin figures came in at 15.59% (Q4 2025), 6.01% (Q3 2025), and 27.27% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -122.23% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -12.88% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | -15.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.59% |
| Sep 30, 2025 | -6.01% |
| Jun 30, 2025 | -27.27% |
| Mar 31, 2025 | -17.47% |
| Dec 31, 2024 | -28.93% |
| Sep 30, 2024 | -23.75% |
| Jun 30, 2024 | -34.59% |
| Mar 31, 2024 | -40.97% |
| Dec 31, 2023 | -26.90% |
| Sep 30, 2023 | -44.23% |
| Jun 30, 2023 | -36.18% |
| Mar 31, 2023 | -38.06% |
| Dec 31, 2022 | -62.30% |
| Sep 30, 2022 | -21.95% |
| Jun 30, 2022 | -21.47% |
| Mar 31, 2022 | -133.16% |
| Dec 31, 2021 | -33.01% |
| Sep 30, 2021 | -25.75% |
| Jun 30, 2021 | -24.54% |
| Mar 31, 2021 | -130.46% |